1.止吐作用-由抑制骨髓之化學接收器引發區而產生。

2.抗精神病作用-一般認為由阻斷在大腦之包突後多巴胺(dopamine)接受器而改善精神病狀態，也可產生alpha-腎上腺素激導性阻斷作用，而抑制下視丘及垂體之激素釋出。

3.鎮靜作用-一般認為導致間接降低腦幹網狀系統之興奮而產生。

精神病狀態、噁心、嘔吐。

Absorption
May be erratic. C max shows large interindividual differences. Food slows the absorption and decreases C max 23% and AUC 13%.

Distribution
Large volume of distribution; crosses the placenta and is distributed into breast milk. Protein binding is at least 90%.

Metabolism
Hepatic to active and inactive metabolites.

Elimination
Renal and biliary, with some enterohepatic recycling.

Onset
10 to 20 min (IM).

Peak
4 to 7 days (antipsychotic effect).

Duration
3 to 4 h (IM).

Alcohol or other CNS depressants
May result in increased CNS depression and may precipitate dystonic reactions.

Anticholinergics
May reduce therapeutic effects of prochlorperazine and worsen anticholinergic effects.

Barbiturate anesthetics
Frequency and severity of neuromuscular excitation and hypotension may be increased.

Beta-blockers
May result in increased plasma levels of beta-blocker and prochlorperazine.

Cisapride, sparfloxacin
The risk of life-threatening cardiac arrhythmias, including torsades de pointes, may be increased.

Guanethidine
Hypotensive action of guanethidine may be inhibited.

Metrizamide
Possibility of seizure may be increased when subarachnoid metrizamide injection is used.

Paroxetine
Plasma levels of prochlorperazine may be elevated, increasing the risk of adverse reactions.